› 5ghv

X-ray diffraction
2.8Å resolution

Crystal structure of an inhibitor-bound Syk

Released:
DOI: 10.2210/pdb5ghv/pdb
PDB entry 5ghv coloured by chain, front view.
PDB entry 5ghv coloured by chain, side view.
PDB entry 5ghv coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs.
Lee SJ, Choi JS, Han BG, Kim HS, Song HJ, Lee J, Nam S, Goh SH, Kim JH, Koh JS, Lee BI
FEBS J 283 3613-3625 (2016)
PMID: 27504936

Function and Biology Details

Reaction catalysed: 
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate
Biochemical function:
Biological process:
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
monomeric (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-155056 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
Tyrosine-protein kinase SYK Chains: A, B
Molecule details ›
Chains: A, B
Length: 290 amino acids
Theoretical weight: 33.9 KDa
Source organism: Homo sapiens
Expression system: Spodoptera frugiperda
UniProt:
  • Canonical: P43405 (Residues: 356-635; Coverage: 44%)
Gene name: SYK
Sequence domains: Protein tyrosine and serine/threonine kinase
Structure domains:

Ligands and Environments

1 bound ligand:
Ligand X5G 2 x X5G
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: PAL/PLS BEAMLINE 7A (6B, 6C1)
Spacegroup: P1
Unit cell:
a: 40.269Å b: 41.501Å c: 85.091Å
α: 89.99° β: 90.01° γ: 98.9°
R-values:
R R work R free
0.217 0.217 0.227
Expression system: Spodoptera frugiperda

Quick links

Citations

6 citation in other articles

Spleen tyrosine kinase SYK(L) interacts with YY1 and coordinately suppresses SNAI2 transcription in lung cancer cells.
Gao et al. (2018)
5 more

1 mention without citation

Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs.
Lee et al. (2016)